pyrazines has been researched along with piperidines in 179 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (5.59) | 18.7374 |
| 1990's | 10 (5.59) | 18.2507 |
| 2000's | 16 (8.94) | 29.6817 |
| 2010's | 95 (53.07) | 24.3611 |
| 2020's | 48 (26.82) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashida, W; Kawai, C; Kumada, T | 1 |
| Gwilt, M; Henderson, CG; Orme, J; Rourke, JD | 1 |
| Baskin, EP; Brookes, LM; Claremon, DA; Lynch, JJ; Selnick, HG; Serik, CM; Wallace, AA | 1 |
| Brookes, LM; Claremon, DA; Lynch, JJ; Selnick, HG; Stupienski, RF; Wallace, AA | 1 |
| Barrett, JE; Brady, LS | 1 |
| Clineschmidt, BV; Pettibone, DJ; Reiss, DR; Robinson, JL | 1 |
| Barrett, JE; Mansbach, RS | 1 |
| Gudelsky, GA; Koenig, JI; Meltzer, HY | 1 |
| Foks, H; Janowiec, M; Pancechowska-Ksepko, D; Zwolska-Kwiek, Z | 1 |
| Bonta, IL; Frankhuyzen, AL | 1 |
| Neurath, G | 1 |
| Bowman, Z; Cooper, CM; Stanton, HC | 1 |
| Dawson, GR; Iversen, SD | 1 |
| MacKenzie, I; Saville, VL; Waterfall, JF | 1 |
| Fuller, RW; Hemrick-Luecke, SK | 1 |
| Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T | 1 |
| Cheng, J; Kamiya, K; Kodama, I; Lee, JK; Suzuki, R; Toyama, J | 1 |
| Dekeyne, A; Girardon, S; Millan, MJ | 1 |
| Blagosklonny, MV | 1 |
| Cheson, BD | 1 |
| Cunningham, KA; Filip, M; McCreary, AC | 1 |
| GYLYS, JA; MUCCIA, PM; TAYLOR, MK | 1 |
| OHTA, A | 1 |
| Dai, Y; Grant, S; Rahmani, M | 1 |
| Shiotsu, Y | 1 |
| Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Albert, M; Ichikawa, E; Kanai, M; Shibasaki, M; Suzuki, M; Yabu, K | 1 |
| Beno, BR; Conway, CM; Dubowchik, GM; Gao, Q; Huang, H; Macor, JE; Michne, JA; Torrente, JR; Wu, D; Xu, C; Zuev, D | 1 |
| Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G | 1 |
| Beers, DS; Brodbeck, RM; Chenard, BL; Guo, Q; Hammer, J; Hutchison, AJ; Kershaw, M; Krause, JE; Mao, J; Maynard, GD; Near, KE; Wustrow, DJ; Yuan, J; Zhao, H; Zhou, D | 1 |
| Augustyns, K; Chen, X; De Cock, H; De Meester, I; Dubois, V; Lambeir, AM; Scharpé, S; Van der Veken, P; Van Ginneken, C | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Cox, JM; Edmondson, SD; Eiermann, GJ; He, H; Lyons, KA; Mastracchio, A; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Weber, AE; Wu, JK; Xu, S; Zhu, B | 1 |
| Brennan, FX; Bryant, RW; Devantier, HR; Long, DJ; Palmer, RK; Salemme, FR | 1 |
| Fujihara, H; Hashimoto, H; Nagatomo, T; Ohbuchi, T; Otsubo, H; Saito, T; Suzuki, H; Ueta, Y; Yokoyama, T | 1 |
| Cefalu, WT | 1 |
| Kuritzky, L | 1 |
| Scheen, AJ | 2 |
| Gerich, J | 1 |
| Boudes, P; Viereck, C | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Ohmachi, K | 1 |
| Grant, S; Holkova, B | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Cui, W; Li, H; Liu, L; Lv, J; Zhang, S | 1 |
| Colby-Germinario, SP; Ibanescu, RI; Mespléde, T; Moisi, D; Oliveira, M; Quashie, PK; Schader, SM; Wainberg, MA | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Conway, SM; Neisewander, JL; Pentkowski, NS; Pockros, LA; Ullman, TE; Zwick, KR | 1 |
| Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Hammarström, LG; Lundbäck, T; Rottenberg, ME; Sjöberg, B; Svensson, R; Vodnala, SK | 1 |
| Bakris, GL; Flynn, C | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H | 1 |
| Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y | 1 |
| Ayaori, M; Iizuka, M; Ikewaki, K; Iwakami, N; Komatsu, T; Murakami, T; Nakaya, K; Ogura, M; Sasaki, M; Sato, H; Takase, B; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Chen, Y; Deng, Y; Deng, ZK; He, ZM; Li, YY; Tao, SD; Yu, L; Zhang, X | 1 |
| Fujita, H; Hayashi, H; Kikuchi, N; Komatsu, K; Komatsu, T; Murayama, H; Narita, T; Ohshiro, H; Sato, S; Taniai, H; Yamada, Y | 1 |
| Chen, W; Li, M; Qiao, J; Su, W; Sui, N; Yang, Y; Zhang, H; Zhang, Q | 1 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Bègue, L; Bell, R; Duke, AA; Gilmore, PE; Page, D | 1 |
| Blum, KA; Maddocks, K | 1 |
| Tibaldi, JM | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Chen, S; Dai, Y; Grant, S; Jones, R; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L | 1 |
| Baz, RC; Bose, P; Colevas, AD; Coppola, D; Dawson, J; Doyle, LA; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Honeycutt, C; Kang, L; Kmieciak, M; Peer, CJ; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Sankala, H; Shrader, E; Stuart, RK; Sullivan, D; Tombes, MB; Wan, W; Weir-Wiggins, C; Wellons, M | 1 |
| Bartlett, M; de Vicente, J; Hekmat-Nejad, M; Henningsen, R; Hermann, JC; Jin, S; Kuglstatter, A; Lemoine, R; Li, H; Lovey, AJ; Menke, J; Niu, L; Patel, V; Petersen, A; Setti, L; Shao, A; Soth, M; Tivitmahaisoon, P; Vu, MD | 1 |
| Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W | 1 |
| Govindarasu, K; Kavitha, E; Suresh, M; Syed Ali Padusha, M | 1 |
| Abraham, WM; Baettig, U; Collingwood, SP; Coote, KJ; Czarnecki, S; Danahay, H; Ethell, B; Faller, T; Gosling, M; Groot-Kormelink, PJ; Harris, J; Lock, R; Paisley, D; Poll, CT; Sabater, J; Schumacher, A; Smith, NJ; Sugar, R; Tweed, M; Vyas, M; Watson, H; Williams, G; Young, A | 1 |
| Castillo, JJ; Ghobrial, IM; Treon, SP | 1 |
| Bodo, J; Chen-Kiang, S; Di Liberto, M; Durkin, L; Elemento, O; Eng, K; Hsi, ED; Shetty, S; Smith, MR; Zhao, X | 1 |
| Treon, SP | 1 |
| Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H | 1 |
| Bartho, L; Bencsik, T; Sandor, Z | 1 |
| Aimone, LD; Ator, MA; Bacon, ER; Gruner, JA; Hudkins, RL; Marino, MJ; Mathiasen, JR; Raddatz, R; Williams, M | 1 |
| Stein, EM | 1 |
| Chen, CH; Chen, YN; Chen, Z; Deng, Z; Fekkes, P; Firestone, B; Fodor, M; Fortin, PD; Fridrich, C; Garcia Fortanet, J; Grunenfelder, D; Ho, S; Kang, ZB; Karki, R; Kato, M; Keen, N; LaBonte, LR; LaMarche, MJ; Larrow, J; Lenoir, F; Liu, G; Liu, S; Lombardo, F; Majumdar, D; Meyer, MJ; Palermo, M; Perez, L; Pu, M; Ramsey, T; Sellers, WR; Shultz, MD; Stams, T; Towler, C; Wang, P; Williams, SL; Zhang, JH | 1 |
| Chernoff, J; Prudnikova, TY | 1 |
| Liu, C; Liu, D; Tsui, ST; Wu, J | 1 |
| Brown, JR; Davids, MS; Deng, J; Fernandes, SM; Isik, E; Letai, A | 1 |
| Kaur, V; Swami, A | 1 |
| Andritsos, LA; Awan, F; Beckwith, K; Byrd, JC; Caligiuri, MA; Cheney, C; Do, P; Flynn, JM; Fraietta, JA; Gordon, A; Johnson, AJ; Jones, JA; June, CH; Lehman, AM; Long, M; Maddocks, KJ; Maus, MV; Mundy, BL; Muthusamy, N; Woyach, JA | 1 |
| Fayad, L; Fowler, N; Jain, P; Kanagal-Shamanna, R; Medeiros, LJ; Nastoupil, L; Oki, Y; Romaguera, J; San Lucas, FA; Wang, M; Westin, JR | 1 |
| Araya, EI; Chichorro, JG; Dos Reis, RC; Kopruszinski, CM; Nones, CFM; Oliveira, LL; Rae, GA; Souza, RF | 1 |
| Bantscheff, M; Dittus, L; Muelbaier, M; Werner, T | 1 |
| Hussar, DA | 1 |
| Scott, A | 1 |
| Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG | 1 |
| Hallur, G; Mullangi, R; Saini, NK; Sulochana, SP; Tamizharasan, N; Zainuddin, M | 1 |
| Coulter, EM; Cuthill, K; Devereux, S; Folarin, N; Mele, S; Patten, PEM; Pepper, A; Phillips, EH; Townsend, W | 1 |
| Arnoult, E; Gunnet, J; Hall, M; Huang, H; Liu, J; Martin, T; Meegalla, SK; Otieno, M; Paul Lee, S; Player, MR; Pocai, A; Rady, B; Silva, J; Wang, Y; Xu, J; Zhao, S | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ninomiya, T; Ohashi, K; Tabata, M; Tomida, S | 1 |
| Baum, A; Beck, J; Engelhardt, H; Gerlach, D; Gerstberger, T; Hofmann, MH; Kaya, O; Kraut, N; Popow, J; Savarese, F; Scharn, D; Schweifer, N; Tontsch-Grunt, U; Zuber, J | 1 |
| Brandl, R; Busygina, K; Deckmyn, H; Jamasbi, J; Lorenz, R; Seiler, T; Siess, W; Weber, C | 1 |
| Awan, FT; Jurczak, W | 1 |
| Liu, Y; Ran, F; Wang, ML; Yang, D; Zhang, D; Zhang, Z; Zhao, G | 1 |
| Göckeritz, E; Hallek, M; Hassenrück, F; Herter, S; Klein, C; Knödgen, E; Krause, G; Midda, SH; Neumann, L; Vondey, V | 1 |
| Asahina, S; Azuma, K; Fukuoka, M; Hayashi, H; Hida, T; Ikeda, S; Inoue, A; Iwamoto, Y; Kiura, K; Komatsu, K; Morita, S; Nakagawa, K; Nakagawa, T; Nishio, M; Satouchi, M; Sugawara, S; Takeda, K | 1 |
| Akazawa, R; Azuma, K; Fukuoka, M; Hayashi, H; Inoue, A; Kaneko, Y; Kang, JH; Kim, SW; Kiura, K; Morita, S; Murakami, H; Nakagawa, K; Nakagawa, T; Nishio, M; Nokihara, H; Park, K; Seto, T; Shimazaki, M; Takeda, K; Tsai, CM; Yang, JC | 1 |
| Clifford, H; Hardy, AT; Hughes, CE; Huissoon, AP; Malcor, JD; Montague, SJ; Nicolson, PLR; Nock, SH; Pollitt, AY; Pratt, G; Thomas, MR; Tomlinson, MG; Watson, CN; Watson, S; Watson, SP | 1 |
| Carrasco, YR; de Bruijn, MJW; Gardeta, SR; Hendriks, RW; Merino-Cortes, SV; Roman-Garcia, S | 1 |
| Bonhaus, D; Khan, A; Koike, MA; Masliah, E; Price, DL; Rockenstein, E; Wrasidlo, W | 1 |
| da Cunha-Bang, C; Niemann, CU | 1 |
| Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W | 1 |
| Długosz-Danecka, M; Jurczak, W; Wang, M | 1 |
| Garcia, C; Levade, M; Payrastre, B; Series, J; Sié, P; Viaud, J; Ysebaert, L | 1 |
| Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA | 1 |
| Bernlochner, I; Busygina, K; Denzinger, V; Lorenz, R; Siess, W; Weber, C | 1 |
| Awan, FT; Bibikova, E; Brown, JR; Byrd, JC; Charuworn, P; Frigault, MM; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Linghu, B; Pagel, JM; Patel, P; Schuh, A; Stephens, DM; Wang, MH; Woyach, J | 1 |
| Hirano, M; Kaneko, N; Konagai, S; Koshio, H; Kuromitsu, S; Matsuya, T; Mori, M; Sakagami, H; Takeuchi, M; Tanaka, H; Yamamoto, H; Yamanaka, Y; Yuri, M | 1 |
| Alinari, L; Bond, DA; Maddocks, K | 1 |
| Felemban, R; François-Moutal, L; Gokhale, V; Khanna, M; Khanna, R; Miranda, VG; Perez-Miller, S; Sayegh, MR; Scott, DD; Zarnescu, DC | 1 |
| Brocato, RL; Hooper, JW | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Al Zoubi, S; Chiazza, F; Coldewey, SM; Collino, M; Collotta, D; Martin, L; O'Riordan, CE; Purvis, GSD; Stiehler, L; Thiemermann, C; Wissuwa, B | 1 |
| Castillo, JJ; Treon, SP | 1 |
| Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
| Aguilar-Company, J; Los-Arcos, I; Ruiz-Camps, I | 1 |
| Daikopoulou, V; Papasotiriou, I; Parsonidis, P; Serafeim, AP; Shaik, M; Vlachou, I | 1 |
| Hiramoto, M; Hirano, M; Kaneko, N; Koshio, H; Matsuya, T; Mori, M; Sakagami, H; Takeuchi, M; Tanaka, H; Yamanaka, Y | 1 |
| Dean, JP; Gururaja, T; Hill, RJ; Hopper, M; Kinoshita, T; Mongan, A | 1 |
| Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Campbell, M; Hanna, KS; Husak, A; Sturm, S | 1 |
| Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M | 1 |
| Bhalla, S; Gabrilove, J; Sigel, K; Thibaud, S; Tremblay, D; Zimmerman, B | 1 |
| Lu, J; Wang, M; Wang, S; Yang, CY | 1 |
| Beylot-Barry, M; Protin, C; Recher, C; Sibaud, V; Vigarios, E; Ysebaert, L | 1 |
| Garjonyte, R; Melvydas, V; Skridlaite, G; Svediene, J; Vaiciuniene, J | 1 |
| Bond, DA; Maddocks, KJ | 1 |
| Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H | 1 |
| Fancher, KM; Pappacena, JJ | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Jiang, Z; Lin, G; Shi, L; Wang, Y; Zhang, Y | 1 |
| Callender, LA; Coldewey, SM; Collino, M; Collotta, D; Ferreira Alves, G; Greaves, DR; Krieg, N; Mohammad, S; O'Riordan, CE; Purvis, GSD; Sheikh, MH; Thiemermann, C; Wissuwa, B | 1 |
| Bartoli, L; Messori, A | 1 |
| Giannarelli, D; Molica, S; Montserrat, E | 1 |
| Danilov, AV; Persky, DO | 1 |
| Lamanna, N; Lipsky, A | 1 |
| Lim, KJC; Tam, CS | 1 |
| Macip, S; Massip-Salcedo, M; Qusairy, Z; Rada, M | 1 |
| Benner, B; Carson, WE | 1 |
| Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L | 1 |
| Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Allan, JN; Cheson, BD; Coleman, M; Frigault, MM; Izumi, R; Jones, D; Kipps, TJ; Patel, P; Quah, C; Raman, RK; Rogers, KA; Sharman, JP; Thompson, PA; Wang, MH | 1 |
| Cao, J; Fan, X; Jiang, L; Liu, Y; Wang, X; Wang, Z; Xia, Y; Yan, M | 1 |
| Ahn, IE; Baptista, MJ; Blackburn, A; Eik, D; Gaglione, EM; Kendall, EK; Keyvanfar, K; Mhibik, M; Qi, J; Rader, C; Sun, C; Wiestner, A | 1 |
| Aldon, Y; Armanasco, N; Harman, S; Herrera, C; Nuttall, J; Rogers, P; Shattock, RJ; Stieh, D; Ziprin, P | 1 |
| Mato, AR; Thompson, MC | 1 |
| Woyach, JA | 1 |
| Ahn, IE; Brown, JR | 1 |
| Li, J; Miao, Y; Xu, W | 1 |
| Mulder, TA; Österborg, A; Palma, M | 1 |
| Byrd, JC; Chanan-Khan, A; Furman, RR; Garcia-Marco, JA; Ghia, P; Hamdy, A; Higgins, K; Hillmen, P; Illés, A; Izumi, R; Jurczak, W; Kater, AP; Kay, N; Lepretre, S; Mato, A; O'Brien, S; Patel, P; Pinilla-Ibarz, J; Robak, T; Rothbaum, W; Seymour, JF; Sohoni, S; Stilgenbauer, S; Yenerel, MN | 1 |
| Mungmunpuntipantip, R; Wiwanitkit, V | 1 |
| Dawar, R; Drusbosky, LM; Ikpeazu, CV; Rodriguez, E | 1 |
| Castillo, JJ; Sarosiek, S; Treon, SP | 1 |
| Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P | 1 |
| Gaballa, S; Pinilla-Ibarz, J | 1 |
| Bohne, LJ; Dorey, TW; Jansen, HJ; Jones, DL; Liu, Y; Rose, RA; Tuomi, JM | 1 |
| Shah, HR; Stephens, DM | 1 |
| Allsup, DJ; Arman, M; Booth, Z; Caserta, S; Chacko, AR; Hart, SP; Jarvis, J; Khan, S; Naylor-Adamson, L; Rivero, F | 1 |
| Bhattacharyya, A; Kim, J; Truong, K; Wells, J | 1 |
| Borbely, J; Egyed, M; Illes, A; Lueff, S | 1 |
| Black, GS; Byrd, JC; Huang, X; Marth, GT; Misra, S; Qiao, Y; Rogers, KA; Stephens, DM; Tarapcsak, S; Woyach, JA | 1 |
57 review(s) available for pyrazines and piperidines
| Article | Year |
|---|---|
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol | 1992 |
[Nitrogen compounds of tobacco smoke].
Topics: Acridines; Alkaloids; Alkanes; Amines; Amino Acids; Aniline Compounds; Carbazoles; Cyanates; Indoles; Isoquinolines; Ketones; Niacinamide; Nicotiana; Nicotine; Nicotinic Acids; Nitriles; Nitrites; Nitrosamines; Piperidines; Plants, Toxic; Pyrazines; Pyridines; Pyrroles; Pyrrolidines; Quinolines; Quinoxalines; Smoking | 1969 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Topics: Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2015 |
Molecularly targeted therapies for acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Clinical Trials as Topic; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2015 |
Second-generation inhibitors of Bruton tyrosine kinase.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2016 |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2017 |
Use of acalabrutinib in patients with mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Drug Design; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug Therapy, Combination; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Acalabrutinib for adults with mantle cell lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Survival Rate | 2019 |
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Animals; Arteries; B-Lymphocytes; Benzamides; Blood Platelets; Cell Differentiation; Genetic Diseases, X-Linked; Hemorrhage; Humans; Imidazoles; Mice; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis | 2019 |
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy | 2019 |
Progress on the Prevention and Treatment of Hantavirus Disease.
Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Hantavirus Infections; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Humans; Immunotherapy; Lactoferrin; Models, Animal; Nucleosides; Orthohantavirus; Piperidines; Pyrazines; Quinazolines; Recombinant Proteins; Ribavirin; Triazoles; Vaccines, Synthetic; Viral Vaccines | 2019 |
What is new in the treatment of Waldenstrom macroglobulinemia?
Topics: Adenine; Antibodies, Monoclonal; Antigens, CD20; Benzamides; Bone Marrow; Disease-Free Survival; Hematology; Humans; Immunoglobulin M; Mutation; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Waldenstrom Macroglobulinemia | 2019 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Communicable Disease Control; Humans; Immune Checkpoint Inhibitors; Infections; Lymphoproliferative Disorders; Piperidines; Purines; Pyrazines; Quinazolinones; Risk; Rituximab; Sulfonamides; Syndrome | 2020 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2020 |
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Eruptions; Ecchymosis; Emollients; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Patient Education as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Severity of Illness Index; Signal Transduction; Skin; Skin Care | 2020 |
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2020 |
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration | 2021 |
Managing toxicities of Bruton tyrosine kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Arrhythmias, Cardiac; Arthralgia; Benzamides; Diarrhea; Hemorrhage; Humans; Hypertension; Infection Control; Infections; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2020 |
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antiviral Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Molecular Targeted Therapy; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazines; Thrombosis | 2021 |
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Targeting Bruton's Tyrosine Kinase in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2021 |
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2021 |
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2021 |
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridazines; Pyrimidines; Triazines | 2021 |
How to Sequence Therapies in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2021 |
BTK Inhibitors in Chronic Lymphocytic Leukemia.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Development; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2021 |
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines | 2022 |
13 trial(s) available for pyrazines and piperidines
| Article | Year |
|---|---|
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol; Japan; Linear Models; Male; Middle Aged; Piperidines; Prospective Studies; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Uracil; Vasodilation | 2013 |
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Chemokine CXCL12; Cross-Over Studies; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Pyrazines; Receptor, Angiotensin, Type 1; Sitagliptin Phosphate; Triazoles; Up-Regulation; Uracil | 2014 |
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Drug Monitoring; Female; Flavonoids; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2014 |
Ibrutinib treatment improves T cell number and function in CLL patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; CTLA-4 Antigen; Female; Humans; Immunosuppressive Agents; Immunotherapy; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Immunologic; T-Lymphocytes | 2017 |
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines | 2018 |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines | 2018 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate | 2019 |
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2021 |
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Benzamides; CD3 Complex; Female; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes | 2021 |
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Prospective Studies; Pyrazines; Survival Rate | 2021 |
110 other study(ies) available for pyrazines and piperidines
| Article | Year |
|---|---|
Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro.
Topics: 4-Aminopyridine; Animals; Anti-Arrhythmia Agents; Benzothiazoles; Calcium Channel Blockers; Disease Models, Animal; Glipizide; Glyburide; Guinea Pigs; In Vitro Techniques; Male; Myocardial Ischemia; Piperidines; Potassium; Potassium Channels; Pyrazines; Pyridines; Sympatholytics; Thiazoles; Ventricular Fibrillation | 1992 |
Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Ferrets; Heart; Hypoxia; In Vitro Techniques; Male; Myocardial Contraction; Phenethylamines; Piperidines; Pyrazines; Pyridines; Refractory Period, Electrophysiological; Sotalol; Sulfonamides; Temperature | 1991 |
Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs.
Topics: Animals; Anti-Arrhythmia Agents; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiology; Female; Heart; Hemodynamics; Male; Myocardial Contraction; Phenethylamines; Piperidines; Pyrazines; Pyridines; Refractory Period, Electrophysiological; Sotalol; Sulfonamides | 1991 |
Effects of serotonin receptor agonists and antagonists on schedule-controlled behavior of squirrel monkeys.
Topics: 5-Hydroxytryptophan; Animals; Cinanserin; Conditioning, Operant; Cyproheptadine; Electroshock; Female; Ketanserin; Male; Metergoline; Methysergide; Piperazines; Piperidines; Pyrazines; Quipazine; Receptors, Serotonin; Saimiri | 1985 |
Characterization of 5-hydroxytryptamine receptors in rat stomach fundus.
Topics: Animals; Binding, Competitive; Brain Chemistry; Gastric Fundus; In Vitro Techniques; Ketanserin; Male; Muscle Contraction; Piperazines; Piperidines; Propranolol; Pyrazines; Quipazine; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Tritium | 1985 |
Effects of MK-212 (6-chloro-2[1-piperazinyl]pyrazine) on schedule-controlled behavior and their reversal by 5-HT antagonists in the pigeon.
Topics: Animals; Columbidae; Conditioning, Operant; Cues; Generalization, Stimulus; Ketanserin; Male; Metergoline; Methysergide; Piperidines; Pyrazines; Receptors, Serotonin; Reinforcement Schedule | 1986 |
Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Body Temperature Regulation; Ketanserin; Male; Methoxydimethyltryptamines; Pindolol; Piperidines; Pyrazines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Spiperone; Tetrahydronaphthalenes | 1986 |
[Studies of pyrazine derivatives. XXV. Synthesis and the tuberculostatic activity of the products of reaction of 5-(6-methoxy- and 5-(6 morpholinopyrazinyl)-1,3,4-oxadiazol-2-thione with amines].
Topics: Chemical Phenomena; Chemistry; Culture Media; Cyclohexylamines; In Vitro Techniques; Morpholines; Mycobacterium tuberculosis; Oxadiazoles; Piperidines; Propylamines; Pyrazines; Thiones | 1988 |
Effect of mianserin, a potent anti-serotonin agent, on the isolated rat stomach fundus preparation.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Binding Sites; Calcium; Chlorpromazine; Cyproheptadine; Dextroamphetamine; Dibenzazepines; Dioxins; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Methysergide; Morphine; Muscle Contraction; Phenoxybenzamine; Piperidines; Propranolol; Pyrazines; Rats; Receptors, Drug; Scopolamine; Serotonin; Serotonin Antagonists; Stomach; Tryptamines | 1974 |
Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats.
Topics: Animals; Carbon Isotopes; Cardiomegaly; DNA; Female; Glycine; Isocarboxazid; Isoniazid; Isoproterenol; Monoamine Oxidase Inhibitors; Myocardium; Nialamide; Nucleic Acids; Pargyline; Phenelzine; Piperidines; Pyrazines; Rats; RNA; Tranylcypromine | 1970 |
The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.
Topics: Animals; Avoidance Learning; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cholinesterase Inhibitors; Conditioning, Classical; Discrimination Learning; Donepezil; Dose-Response Relationship, Drug; Indans; Learning; Memory; Mice; Oxadiazoles; Pain Threshold; Parasympathomimetics; Physostigmine; Piperidines; Pyrazines; Quinuclidines; Rats; Receptors, Muscarinic; Thiophenes | 1993 |
Differential class III and glibenclamide effects on action potential duration in guinea-pig papillary muscle during normoxia and hypoxia/ischaemia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Electrophysiology; Glyburide; Guinea Pigs; Heart; Hypoxia; In Vitro Techniques; Microelectrodes; Myocardial Ischemia; Papillary Muscles; Piperidines; Potassium Channels; Pyrazines; Pyridines; Sotalol | 1993 |
Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.
Topics: Animals; Corticosterone; Fluorobenzenes; Indoles; Male; Piperidines; Pyrazines; Quipazine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Urea | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current.
Topics: Action Potentials; Adjuvants, Immunologic; Animals; Anti-Arrhythmia Agents; Delayed Rectifier Potassium Channels; Electric Conductivity; Male; Myocardium; Papillary Muscles; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Pyrazines; Pyridines; Quinolines; Rabbits; Reaction Time; Ventricular Function | 1997 |
Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aminopyridines; Animals; Conditioning, Operant; Ethylamines; Fluorobenzenes; Indoles; Male; Mianserin; Piperazines; Piperidines; Pyrazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Reinforcement, Psychology; Serotonin Antagonists; Serotonin Receptor Agonists; Thiophenes | 1999 |
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cyclosporins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Flavonoids; Hematopoietic Stem Cells; HL-60 Cells; Humans; Jurkat Cells; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Paclitaxel; Piperidines; Poly(ADP-ribose) Polymerases; Pyrazines; Substrate Specificity; Thiazoles | 2001 |
Discriminative stimulus properties of (+/-)-fenfluramine: the role of 5-HT2 receptor subtypes.
Topics: Animals; Discrimination Learning; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Fenfluramine; Fluorobenzenes; Indoles; Ketanserin; Male; Piperidines; Pyrazines; Pyridines; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Reinforcement, Psychology; Serotonin Antagonists; Serotonin Receptor Agonists; Spiro Compounds; Sulfonamides; Thiophenes | 2003 |
Pharmacological and toxicological properties of 2-methyl-3-piperidinopyrazine, a new antidepressant.
Topics: Antidepressive Agents; Humans; Monoamine Oxidase Inhibitors; Piperidines; Pyrazines | 1963 |
[SYNTHESIS OF PULCHERRIMINE AND PULCHERRIMINIC ACIDS].
Topics: Amino Acids, Sulfur; Candida; Chemistry, Pharmaceutical; Piperidines; Pyrazines; Research | 1964 |
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blast Crisis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid, Acute; Leupeptins; Mitogen-Activated Protein Kinases; Multienzyme Complexes; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2003 |
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Humans; I-kappa B Proteins; Imatinib Mesylate; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Piperidines; Pyrazines; Pyrimidines; RNA Polymerase II; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators | 2004 |
New entries in Lewis acid-Lewis base bifunctional asymmetric catalyst: catalytic enantioselective Reissert reaction of pyridine derivatives.
Topics: Aluminum; Catalysis; Isoquinolines; Naphthols; Oxides; Phosphines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Quinolines; Stereoisomerism | 2004 |
Stereoselective synthesis of new conformationally restricted analogues of a potent CGRP receptor antagonist.
Topics: Benzimidazoles; Calcitonin Gene-Related Peptide Receptor Antagonists; Crystallography, X-Ray; Lactams; Molecular Conformation; Molecular Structure; Piperazines; Piperidines; Pyrazines; Stereoisomerism | 2005 |
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured | 2005 |
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction | 2008 |
Aminopyrazine CB1 receptor inverse agonists.
Topics: Animals; Blood Glucose; Combinatorial Chemistry Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Feeding Behavior; Humans; Microsomes, Liver; Molecular Structure; Obesity; Piperidines; Pyrazines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship | 2008 |
Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.
Topics: Animals; Cattle; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Epididymis; Genitalia, Male; Immunoblotting; Immunohistochemistry; Indoles; Isoleucine; Male; Organ Specificity; Piperidines; Pyrazines; Rats; Sitagliptin Phosphate; Species Specificity; Spermatozoa; Testis; Triazoles | 2009 |
Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.
Topics: Animals; Benzimidazoles; Chemistry, Pharmaceutical; Crystallography, X-Ray; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Drug Design; Glucagon-Like Peptide 1; Humans; Hydrolysis; Imidazoles; Inhibitory Concentration 50; Macaca mulatta; Mice; Piperidines; Pyrazines; Pyridines; Rats; Sitagliptin Phosphate; Triazoles | 2009 |
Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.
Topics: Acrylamides; Administration, Oral; Alkaloids; Anilides; Animals; Avoidance Learning; Benzodioxoles; Bridged Bicyclo Compounds, Heterocyclic; Capsaicin; Cinnamates; Diterpenes; Dose-Response Relationship, Drug; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Polyunsaturated Alkamides; Pyrazines; Pyridines; Taste; TRPM Cation Channels; TRPV Cation Channels | 2010 |
TRPV1 gene deficiency attenuates miniature EPSC potentiation induced by mannitol and angiotensin II in supraoptic magnocellular neurons.
Topics: Analysis of Variance; Angiotensin II; Anilides; Animals; Capsaicin; Chelating Agents; Cinnamates; Diuretics, Osmotic; Drug Interactions; Egtazic Acid; Enzyme Inhibitors; In Vitro Techniques; Male; Mannitol; Mice; Mice, Inbred C57BL; Mice, Knockout; Miniature Postsynaptic Potentials; Neurons; Piperidines; Pyrazines; Pyrazoles; Pyridines; Rats; Rats, Wistar; Signal Transduction; Supraoptic Nucleus; TRPV Cation Channels; Vasoconstrictor Agents | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
Identification of antifungal compounds produced by Lactobacillus casei AST18.
Topics: Antifungal Agents; Chromatography, High Pressure Liquid; Culture Media; Dipeptides; Gas Chromatography-Mass Spectrometry; Hydrogen-Ion Concentration; Lactic Acid; Lacticaseibacillus casei; Peptides, Cyclic; Piperidines; Pyrazines; Temperature; Ultrafiltration | 2012 |
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
Topics: Amino Acid Sequence; Anti-HIV Agents; Antibodies, Neutralizing; Cell Line, Tumor; Drug Resistance, Viral; Genes, env; Genotype; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV-1; HIV-2; Humans; Models, Molecular; Mutagenesis, Site-Directed; Piperidines; Polymorphism, Genetic; Protein Structure, Quaternary; Pyrazines; Sequence Alignment; Virus Internalization | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen.
Topics: Animals; Caudate Nucleus; Cocaine; Fluorobenzenes; Gene Expression Regulation; Locomotion; Male; Piperidines; Proto-Oncogene Proteins c-fos; Putamen; Pyrazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2012 |
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
In vitro and in vivo activities of 2-aminopyrazines and 2-aminopyridines in experimental models of human African trypanosomiasis.
Topics: Aminopyridines; Animals; Benzopyrans; Cell Line; Humans; Mice; Mice, Inbred C57BL; Piperidines; Pyrazines; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei gambiense; Trypanosoma brucei rhodesiense; Trypanosomiasis, African | 2013 |
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured | 2013 |
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
[Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2013 |
Effects of 5-hydroxytryptamine 2C receptor agonist MK212 and 2A receptor antagonist MDL100907 on maternal behavior in postpartum female rats.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Piperidines; Postpartum Period; Pyrazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin Antagonists; Serotonin Receptor Agonists | 2014 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Anxiolytic-like effects observed in rats exposed to the elevated zero-maze following treatment with 5-HT2/5-HT3/5-HT4 ligands.
Topics: Aniline Compounds; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; Diazepam; Male; Maze Learning; Oxazines; Piperidines; Propane; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Spiro Compounds; Sulfonamides | 2014 |
Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Cyclin T; Cyclin-Dependent Kinase 9; Cycloheximide; Flavonoids; Gene Expression Regulation; Heat-Shock Proteins; Humans; Indoles; Leupeptins; Membrane Proteins; Mice; Mice, Knockout; Mitochondrial Proteins; Piperidines; Protein Transport; Pyrazines; Pyrroles; RNA, Small Interfering; Sequestosome-1 Protein | 2014 |
Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
Topics: Drug Design; Humans; Janus Kinase 3; Models, Molecular; Molecular Conformation; Molecular Structure; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2014 |
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Synthesis, structural and spectral analysis of 1-(pyrazin-2-yl) piperidin-2-ol by density functional theory.
Topics: Algorithms; Gases; Hydrogen; Magnetic Resonance Spectroscopy; Oxygen; Piperidines; Pyrazines; Software; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Temperature; Thermodynamics; Vibration | 2015 |
NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia.
Topics: Administration, Inhalation; Amiloride; Animals; Epithelial Cells; Epithelial Sodium Channel Blockers; Guanidines; Guinea Pigs; Hyperkalemia; In Vitro Techniques; Mucociliary Clearance; Phenyl Ethers; Piperidines; Pyrazines; Rats; Respiratory Mucosa; Sheep | 2015 |
CCMCL1: a new model of aggressive mantle cell lymphoma.
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Tumor Cells, Cultured | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2015 |
High-Concentration Piperine: Capsaicin-Sensitive and -Insensitive Effects on Isolated Organs.
Topics: Acetanilides; Alkaloids; Animals; Benzodioxoles; Capsaicin; Dose-Response Relationship, Drug; Female; Guinea Pigs; Ileum; In Vitro Techniques; Male; Muscle Contraction; Nifedipine; Piperidines; Polyunsaturated Alkamides; Purines; Pyrazines; Pyridines; Trachea; TRPV Cation Channels; Urinary Bladder | 2015 |
3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Topics: Administration, Oral; Animals; Biological Availability; Brain; Dogs; Drinking; Drug Evaluation, Preclinical; Drug Inverse Agonism; Histamine Agonists; Histamine H3 Antagonists; Humans; Macaca fascicularis; Male; Methylhistamines; Motor Activity; Piperidines; Pyrazines; Rats, Sprague-Dawley; Receptors, Histamine H3; Sleep; Spiro Compounds; Wakefulness | 2016 |
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Topics: Administration, Oral; Allosteric Regulation; Allosteric Site; Animals; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Female; Heterografts; High-Throughput Screening Assays; Humans; Male; Mice, Inbred C57BL; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Piperidines; Protein Conformation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Pyrimidines; Structure-Activity Relationship | 2016 |
The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.
Topics: Acetophenones; Benzopyrans; Cell Line, Tumor; Chromosomes, Human, Pair 11; Drug Synergism; Female; Humans; Ovarian Neoplasms; p21-Activated Kinases; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Signal Transduction | 2017 |
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2017 |
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Resistance; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Mechanisms involved in facial heat hyperalgesia induced by endothelin-1 in female rats.
Topics: Animals; Carbazoles; Diterpenes; Endothelin-1; Face; Female; Hot Temperature; Hyperalgesia; Indole Alkaloids; Nerve Growth Factor; Oligopeptides; Peptides, Cyclic; Piperidines; Pyrazines; Pyridines; Rats; Rats, Wistar; Trigeminal Ganglion | 2017 |
Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors.
Topics: Acrylamides; Adenine; B-Lymphocytes; Benzamides; Cell Line; Humans; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines | 2017 |
New Drugs 2017, part 3.
Topics: Acetamides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitoxins; Bridged Bicyclo Compounds, Heterocyclic; Carbazoles; Chenodeoxycholic Acid; Drug Approval; Humans; Indoles; Morpholinos; Oligonucleotides; Piperidines; Polydeoxyribonucleotides; Pyrazines; Sulfonamides; United States; United States Food and Drug Administration | 2017 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Chemokine CCL3; Chemokine CCL4; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2018 |
LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice.
Topics: Animals; Area Under Curve; Benzamides; Carbon Isotopes; Chromatography, High Pressure Liquid; Drug Stability; Focal Adhesion Kinase 1; Limit of Detection; Liquid-Liquid Extraction; Male; Mice; Mice, Inbred BALB C; Nitrogen Isotopes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry | 2018 |
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; CD79 Antigens; Clonal Anergy; Endocytosis; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2018 |
Discovery of a novel potent GPR40 full agonist.
Topics: Animals; Benzofurans; Biphenyl Compounds; CHO Cells; Cricetulus; Dogs; Glucagon-Like Peptide-1 Receptor; Glucuronides; Humans; Hypoglycemic Agents; Macaca fascicularis; Mice; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Phenylpropionates; Piperidines; Pyrazines; Pyrimidines; Rats; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Sulfones | 2018 |
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Inhibitory Concentration 50; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrrolidines | 2018 |
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Enhancer Elements, Genetic; Flavonoids; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Piperidines; Proteins; Pyrazines; RNA Polymerase II; RNA-Binding Proteins; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Humans; Imidazoles; Male; Middle Aged; Piperidines; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Thrombosis | 2018 |
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cytotoxins; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Rituximab | 2018 |
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Benzamides; Blood Platelets; Carrier Proteins; Genetic Diseases, X-Linked; Humans; Mutation; Peptides; Piperidines; Platelet Activation; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antigens; B-Lymphocytes; Benzamides; Calcium Signaling; Cell Membrane; Cell Polarity; Cell Proliferation; Cells, Cultured; Immunological Synapses; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Microtubule-Organizing Center; Mutation; Phospholipase C gamma; Piperidines; Protein Transport; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell | 2018 |
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cerebral Cortex; Disease Models, Animal; Gene Expression Regulation; Humans; Inflammation; Lewy Body Disease; Mice; Mice, Transgenic; Multiple System Atrophy; Neurons; Parkinson Disease; Piperidines; Protein Aggregation, Pathological; Protein Folding; Pyrazines; Pyrimidines; Retina | 2018 |
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines | 2019 |
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Blood Platelets; Humans; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis | 2019 |
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Topics: Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Pyrrolidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a
Topics: Amyotrophic Lateral Sclerosis; Animals; Base Sequence; Binding Sites; DNA-Binding Proteins; Drosophila melanogaster; Drosophila Proteins; Locomotion; Molecular Docking Simulation; Neuroprotective Agents; Piperidines; Protein Binding; Protein Domains; Pyrazines; RNA; Small Molecule Libraries | 2019 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cecum; Disease Models, Animal; Heart; Heart Diseases; Inflammasomes; Ligation; Male; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Punctures; Pyrazines; Pyrazoles; Pyrimidines; Sepsis | 2019 |
Design, Synthesis, and In Vitro Activity of Pyrazine Compounds.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; HCT116 Cells; Humans; MCF-7 Cells; Piperidines; Protein Structure, Secondary; Protein Tyrosine Phosphatases; Pyrazines; Pyrimidines | 2019 |
Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Cells, Cultured; Female; Humans; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; Piperazines; Piperidines; Pyrazines; Pyrrolidines; Receptors, Antigen, B-Cell; Xenograft Model Antitumor Assays | 2020 |
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Cell Line; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Kinetics; Models, Biological; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2020 |
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Topics: Adenine; Animals; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mice; Neoplasms; Piperidines; Pyrazines; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T-Lymphocytes; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cullin Proteins; Dipeptides; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Ligands; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proteolysis; Pyrazines; Pyrimidines; Pyrrolidines | 2020 |
In vitro inhibition of Saccharomyces cerevisiae growth by Metschnikowia spp. triggered by fast removal of iron via two ways.
Topics: Amino Acids, Sulfur; Antibiosis; Antifungal Agents; Biological Control Agents; Culture Media; Iron; Metschnikowia; Piperidines; Pyrazines; Saccharomyces cerevisiae | 2020 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbidity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inducers; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Fruit and Vegetable Juices; Hematologic Neoplasms; Humans; Lymphoproliferative Disorders; Piperidines; Polypharmacy; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction | 2020 |
Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Topics: Adenine; Animals; Benzamides; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dogs; Percutaneous Coronary Intervention; Piperidines; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Disease Models, Animal; Inflammasomes; Macrophages; Male; Mice; Mice, Inbred CBA; Multiple Organ Failure; Phagocytosis; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sepsis; X-Linked Combined Immunodeficiency Diseases | 2020 |
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Pyrazines; Sulfonamides; Survival Rate | 2021 |
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Repositioning; Gene Expression Regulation; Humans; Piperidines; Pyrazines; SARS-CoV-2 | 2021 |
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Line; Cell Line, Tumor; Chickens; Chlorocebus aethiops; COS Cells; Cysteine; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Threonine | 2021 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
Topics: Adenine; Benzamides; Drug Interactions; Glucuronosyltransferase; Humans; Isoenzymes; Molecular Structure; Piperidines; Pyrazines | 2021 |
The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate.
Topics: CD4 Antigens; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Piperazines; Piperidines; Pre-Exposure Prophylaxis; Pyrazines | 2021 |
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2021 |
Alectinib, COVID-19 and favipiravir.
Topics: Amides; Carbazoles; COVID-19; Humans; Piperidines; Pyrazines; SARS-CoV-2 | 2021 |
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunocompromised Host; Infections; Lymphopenia; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazines; Quinazolinones; Retrospective Studies; Risk Factors; Sulfonamides; Young Adult | 2021 |
Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis.
Topics: Action Potentials; Adenine; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Benzamides; Cardiac Electrophysiology; Mice; Myocytes, Cardiac; Piperidines; Pyrazines; Sinoatrial Node | 2021 |
Is there a role for anti-CD20 antibodies in CLL?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines; Rituximab; Sulfonamides | 2021 |
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Platelets; Escherichia coli; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Activation; Platelet Aggregation; Protein Kinase Inhibitors; Pyrazines; Receptors, IgG; Staphylococcus aureus | 2021 |
A uniquely distributed purpuric drug eruption from acalabrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Eruptions; Humans; Piperidines; Protein Kinase Inhibitors; Purpura; Pyrazines; Quality of Life | 2022 |
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2022 |